Swiss-Italian clinical-stage immuno-oncology company developing neoantigen cancer vaccines.
概要
Nouscom AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland with an office in Rome, Italy. Founded in 2015, it develops neoantigen-based cancer immunotherapies including the viral-vector vaccine candidate NOUS-209.